Achieve Life Sciences announces completion of enrollment in ORCA-OL trial

Achieve Life Sciences announced an update on the ORCA-OL clinical trial, evaluating long-term exposure of the novel 3 mg cytisinicline treatment dosing regimen in individuals who smoke cigarettes or vape nicotine. Enrollment for the ORCA-OL trial has been completed with an enrollment of 479 participants at 29 clinical trial sites across the United States. All clinical sites and participants were previously involved in Achieve’s ORCA “Ongoing Research of Cytisinicline for Addiction” program for smoking and e-cigarette cessation studies, which is thought to have facilitated the rapid enrollment of this trial in just over four months